Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Citius Pharmaceuticals ( (CTXR) ) just unveiled an announcement.
On March 10, 2026, Citius Oncology reported positive topline results from an investigator-initiated Phase 1 trial led by the University of Pittsburgh evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic cancers. The dose-escalation study, which enrolled heavily pretreated patients with limited options, found no unexpected safety signals or serious immune-related adverse events across dose levels and established a recommended dose for further study.
Among 21 evaluable patients, the trial showed a 24% objective response rate and a 48% clinical benefit rate, suggesting that LYMPHIR’s T-regulatory cell depletion may enhance the anti-tumor effect of PD-1 checkpoint inhibition in ovarian and endometrial cancers. While the Phase 1 study was not powered to confirm efficacy, the favorable safety profile and early efficacy signal highlight the potential for LYMPHIR to expand its role beyond cutaneous T-cell lymphoma and could support Citius Oncology’s broader immuno-oncology ambitions if confirmed in later-stage trials.
The most recent analyst rating on (CTXR) stock is a Hold with a $0.94 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.
The score is primarily constrained by significant ongoing losses and sustained cash burn, despite a low-debt balance sheet. Technicals show a short-term improvement but not a confirmed long-term uptrend. Valuation remains difficult due to negative earnings, partially offset by a positive clinical-development update that provides near-term optimism but carries early-stage uncertainty.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. It develops and commercializes targeted cancer therapies, led by LYMPHIR, an FDA-approved treatment for adults with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma, addressing an estimated initial market exceeding $400 million that management views as growing and underserved.
The company’s strategy is supported by a portfolio of intellectual property protections, including orphan drug status, complex manufacturing technology, trade secrets and pending patents related to immuno-oncology use in combination with checkpoint inhibitors. This positioning is intended to strengthen Citius Oncology’s competitive edge in the targeted oncology and immuno-oncology segments in the U.S. and other licensed markets.
Average Trading Volume: 858,074
Technical Sentiment Signal: Strong Sell
Current Market Cap: $18.77M
Find detailed analytics on CTXR stock on TipRanks’ Stock Analysis page.